EMEA-003132-PIP01-21
Key facts
| Active substance |
Sunvozertinib
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0058/2022
|
| PIP number |
EMEA-003132-PIP01-21
|
| Pharmaceutical form(s) |
All pharmaceutical forms
|
| Condition(s) / indication(s) |
Treatment of non-small cell lung cancer
|
| Route(s) of administration |
All routes of administration
|
| Contact for public enquiries |
Dizal (Jiangsu) Pharmaceutical Co., Ltd
E-mail: info@dizalpharma.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|